Sanofi India Limited — Important, 24-04-2025: General Updates

Sanofi India Limited has disclosed that the Commissioner of Central GST & Central Excise, Vadodara II, has confirmed a demand for Rs. 5.26 Cr along with an equivalent penalty. This demand pertains to the reversal of CENVAT credit, related to the company's inability to demonstrate full credit reversal for both exempt and non-exempt products. The company plans to file an appeal against this order. Fortunately, Sanofi has indicated that this development will not have a material impact on its financial or operational activities, although investors should monitor the situation closely for any potential changes in the future.